Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 02 - 28 exchanges : Nasdaq save search
GENFIT Announces Solid Revenues and Cash Position as of December 31, 2021
Published: 2022-02-28 (Crawled : 14:00) - globenewswire.com
GNFT | $3.44 -6.01% -6.4% 2.2K
|
Health Technology
|
| O: 0.27%
H: 0.27%
C: -1.86%
positive
Vislink to Join Dorna Sports and MotoGP™ at Mobile World Congress Barcelona 2022
Published: 2022-02-28 (Crawled : 14:20) - globenewswire.com
VISL | $4.08 1.58% 1.56% 7.5K
|
Electronic Technology
|
| O: -0.11%
H: 5.49%
C: 1.65%
mobile
Ocular Therapeutix™ Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update
Published: 2022-02-28 (Crawled : 20:20) - ocutx.gcs-web.com
OCUL | News | $5.0 -1.48% -1.5% 2.3M
|
Health Technology
|
| O: -8.24%
H: 12.7%
C: 7.42%
financial results ocular report results
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Published: 2022-02-28 (Crawled : 16:20) - ir.ateapharma.com
AVIR | $3.725 1.5% 1.48% 180K
|
Health Technology
|
| O: 10.41%
H: 4.57%
C: -7.71%
als financial results report results
KalVista Pharmaceuticals Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief From HAE Attacks in Patients
Published: 2022-02-28 (Crawled : 16:20) - ir.kalvista.com
KALV | News | $11.21 -2.01% -2.05% 190K
|
Health Technology
|
| O: -0.62%
H: 2.63%
C: -0.06%
kvd900 treatment als
BrainChip appoints Antonio J. Viana as Chairman of the Board
Published: 2022-02-28 (Crawled : 00:00) - brainchipinc.com
AIP | $6.54 0.62% 0.61% 60K
|
Information
|
| O: -8.19%
H: 0.67%
C: -8.14%
chip air
Deutsche Bank Media, Internet and Telecom Conference Webcast
Published: 2022-02-28 (Crawled : 00:00) - nexstar.tv
NXST | News | $163.05 1.27% 1.25% 260K
|
Consumer Services
|
| O: 6.78%
H: 1.77%
C: -0.91%
internet conference media
Miner Suffers Fatal Injury at Berwind Mine
Published: 2022-02-28 (Crawled : 00:00) - prnewswire.com
METC | $14.67 -6.08% -6.48% 790K
|
Energy Minerals
|
| O: 3.6%
H: 9.8%
C: 8.37%
Broadwind Announces $13 Million in New Tower Orders
Published: 2022-02-28 (Crawled : 00:00) - globenewswire.com
BWEN | $2.11 -3.21% -3.81% 99K
|
Producer Manufacturing
|
| O: 14.5%
H: 0.0%
C: 0.0%
order
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2022-02-28 (Crawled : 00:00) - globenewswire.com
SRPT | $117.065 0.09% 0.09% 440K
|
Health Technology
|
| O: 0.63%
H: 0.62%
C: -0.11%
therapeutics nasdaq grant granted
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -1.15%
H: 1.44%
C: 1.12%
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
ntla-2001 crispr disease intel phase 1 therapy
Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
EDIT | News | $5.465 -2.41% -2.47% 1.6M
|
Health Technology
|
| O: -0.65%
H: 4.53%
C: 1.97%
ema patent crispr
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -1.15%
H: 1.44%
C: 1.12%
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
ntla-2001 crispr disease intel phase 1 therapy
Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
PPRUF | News | $364.27 37.56% 850
|
Consumer Non-Durables
|
| O: 1.35%
H: 0.69%
C: -2.73%
PPRUY | News | $36.96 -0.11% 220K
|
Manufacturing
|
| O: -3.29%
H: 2.78%
C: 0.27%
PCVX | $60.89 -1.15% -1.17% 660K
|
Health Technology
|
| O: -0.66%
H: 3.83%
C: 3.21%
STRO | $3.73 -1.06% -1.07% 720K
|
Health Technology
|
| O: -1.13%
H: 3.08%
C: 1.59%
financial results report results
Fusion Pharmaceuticals to Participate at the Cowen 42nd Annual Health Care Conference
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
FUSN | $21.42 0.47% 0.47% 1.9M
|
Health Technology
|
| O: 0.33%
H: 3.93%
C: -1.64%
health als conference
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X SyndromeProvides 10-year market exclusivity in EU upon regulatory approval
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -4.76%
H: 0.0%
C: 0.0%
als europe drug granted approval drug designation orphan drug grant designation zygel
Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
DSGN | $3.645 -6.3% -6.72% 160K
|
Professional, Scientific, and T...
|
| O: -1.4%
H: 3.68%
C: 1.72%
new drug fda clearance application drug therapeutics fda clearance friedreich's ataxia designation friedreich’s ataxia
Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
NKTR | News | $1.415 4.04% 3.89% 1.1M
|
Health Technology
|
| O: -1.1%
H: 4.15%
C: 3.75%
financial results therapeutics report results
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Recent Corporate Updates
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
HRTX M | $2.805 8.3% 7.66% 6.6M
|
Health Technology
|
| O: -1.72%
H: 1.89%
C: -4.31%
financial results ces therapeutics results
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
APLS G | $48.69 2.2% 2.16% 1.2M
|
Health Technology
|
| O: -0.07%
H: 0.61%
C: 0.07%
als financial results report results
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 870K
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.